Country: Canada
Language: English
Source: Health Canada
VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE)
TEVA CANADA LIMITED
J05AB11
VALACICLOVIR
500MG
TABLET
VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 500MG
ORAL
42
Prescription
NUCLEOSIDES AND NUCLEOTIDES
Active ingredient group (AIG) number: 0128626001; AHFS:
APPROVED
2012-11-01
_TEVA-VALACYCLOVIR (valacyclovir) _ _ _ _Page 1 of 42 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TEVA-VALACYCLOVIR Valacyclovir Tablets Tablets, 500 mg valacyclovir (as valacyclovir hydrochloride), Oral BP Antiviral Agent Teva Canada Limited 30 Novopharm Court Toronto, ON M1B 2K9 Canada www.tevacanada.com Submission Control No: 271297 Date of Initial Authorization: October 01, 2010 Date of Revision: June 29, 2023 _TEVA-VALACYCLOVIR (valacyclovir) _ _ _ _Page 2 of 42 _ _ _ RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions, Immune 06/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ................................................................................. 2 TABLE OF CONTENTS.................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................. 4 1 INDICATIONS ...................................................................................................... 4 1.1 Pediatrics……... ...................................................................................... 4 1.2 Geriatrics .............................................................................................. 4 2 CONTRAINDICATIONS ......................................................................................... 4 4 DOSAGE AND ADMINISTRATION ......................................................................... 4 4.1 Dosing Considerations ........................................................................... 4 4.2 Recommended Dose and Dosage Adjustment ........................................ 5 4.5 Missed Dose .......................................................................................... 7 5 OVERDOSAGE ..................................................................................................... 7 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................ Read the complete document